Clinical Research Directory
Browse clinical research sites, groups, and studies.
OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk
Sponsor: Gangnam Severance Hospital
Summary
Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®). In these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.
Official title: Endocrine Therapies With Ovarian Function Suppression in Premenopausal Node+ Early Breast Cancer With Low Genomic Risk (INTERSTELLAR Trial, KBCSG-25)
Key Details
Gender
FEMALE
Age Range
20 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
418
Start Date
2023-02-06
Completion Date
2033-01
Last Updated
2025-05-22
Healthy Volunteers
No
Conditions
Interventions
Ovarian function suppression with endocrine treatments
* Ovarian function suppression (OFS) with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years. * Either goserelin acetate or leuprorelin Acetate is allowed. * These patients are able to choose bilateral salpingo-oophorectomy instead of OFS. * Chemotherapy is omitted in these patients.
Locations (2)
Gangnam Severance Hospital
Seoul, Korea, South Korea
Seoul National University Hospital
Seoul, South Korea